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Monoclonal antibodies have many attractions as targeting agents for site-specific delivery of drugs (7). An alternative approach to chemical conjugation is to use a bispecific antibody with dual binding activity to link a toxic moiety to a binding moiety with targeting specificity. This approach is being explored with drugs (2), drug-carrier conjugates (3), and ribosome-inhibiting toxins (4, 5) . With such bispecific antibodies, the toxic and targeting moieties could be administered separately, with the smaller size of the separate components giving potentially advantageous tissue penetration. It would also be possible to prelocalize the antibody, giving considerable flexibility in the design of schedules for optimum localization of the toxic moiety. However, it is important to examine in vitro whether a monovalent form of an antibody against a selected tumor-associated antigen can deliver sufficient toxin of choice to an appropriate intracellular compartment to kill cells of the proposed type of target tumor. In this study, a bispecific antibody with specificities for carcinoembryonic antigen (CEA) and the A chain of ricin toxin (RTA) has been produced and examined for its ability, in the presence of RTA, to mediate selective target-cell damage against CEA-expressing gastrointestinal tract tumor cells.
Bispecific antibodies can be produced by chemical conjugation of antibody fragments (5), but fusion of two hybridomas or a hybridoma with immune spleen cells (2, (6) (7) (8) can produce hybridomas giving a continual supply of antibody. Hybridoma to hybridoma fusion was used in the present study, and selection of heterohybrids using a fluorescenceactivated cell sorter was found to be a rapid and convenient method of isolating hybrid hybridomas. From a fusion of an anti-RTA hybridoma (designated 596/ 192) and an anti-CEA hybridoma (NCRC-23), a hybrid hybridoma designated 636, which was found to secrete high levels of antibodies binding to CEA and RTA, was selected and recloned twice.
The maximum yield of bispecific antibody from hybrid hybridomas is 50% of the total immunoglobulin synthesized, but lower proportions of bispecific antibody are produced if heterologous heavy to light chain reassociations occur (9). In the present study, we separated antibodies using agarose-encapsulated hydroxyapatite (IBF Biotechnics, Life Science Laboratories, Luton, UK): anti-RTA reactivity eluted at approximately 0.063 M phosphate, both anti-CEA and anti-RTA reactivities eluted at about 0.087 M, and binding activity for CEA alone eluted at approximately 0.158 M. Antibody fractions were then tested for their ability to bridge between CEA and RTA in a flow cytometric test. Latex beads with CEA covalently coupled to the surface (70) were mixed with putative bispecific antibody and RTA labeled with fluorescein; bound fluorescence was quantitated by flow cytometry. A positive reaction was seen in the intermediate fractions from the column, but not in the early or late fractions or the parent antibodies.
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